Cancer Discov. 2020 Dec;10(12):OF1. doi: 10.1158/2159-8290.CD-NB2020-99. Epub 2020 Nov 9.
A phase II trial shows that a chemotherapy-free regimen of dasatinib and blinatumomab produces molecular responses in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. The study found that 60% of patients had molecular responses after two cycles of blinatumomab and 71% had molecular responses after five cycles.
一项 II 期临床试验表明，达沙替尼联合blinatumomab 的无化疗方案可使费城染色体阳性急性淋巴细胞白血病患者产生分子应答。研究发现，blinatumomab 治疗两个周期后，60%的患者有分子应答，治疗五个周期后，71%的患者有分子应答。
